Results 81 to 90 of about 583,827 (328)

Addressing the challenge of neonatal mortality.

, 2013
Reducing neonatal mortality remains a challenge with an estimated 3.0 million neonatal deaths in 2011, three-quarters of these in sub-Saharan Africa and Southern Asia.
Blencowe, H, Cousens, S
core   +1 more source

Clinical trials design: protocols and endpoints [PDF]

International Journal of Impotence Research, 2000
Over the last decade there has been a proliferation in clinical trials to test agents for the treatment of erectile dysfunction (ED). Many aspects of clinical trials design and conduct and guidelines for future conduct have been the subject of a recent comprehensive review (Rosen R et al.
openaire   +2 more sources

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Mavacamten induces a clinical, hemodynamic, and biomarker response beyond the primary endpoint in EXPLORER-HCM: results from a post hoc machine learning analysis [PDF]

, 2022
Theodore P. Abraham, Amy J. Sehnert, W Anderson, Joshua Landis, W Li, G Kurio, Iacopo Olivotto   +6 more
openalex   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Oral contraceptives combined with interferon β in multiple sclerosis [PDF]

, 2015
Objective: To test the effect of oral contraceptives (OCs) in combination with interferon b (IFN-b) on disease activity in patients with relapsing-remitting multiple sclerosis (RRMS).
Barletta, Valeria T., De Angelis, Floriana, De Giglio, Laura, Gallo, Valentina, Marinelli, Fabiana, Marini, Stefano, Pagano, Veronica A., Pantano, Patrizia, Piattella, Maria C., Pozzilli, Carlo, Tomassini, Valentina   +10 more
core   +3 more sources

Clinical endpoint adjudication [PDF]

The Lancet, 2020
Meah, Mohammed, Denvir, Martin, Mills, Nicholas, Norrie, John, Newby, David   +4 more
openaire   +3 more sources

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action

Canadian Journal of Gastroenterology and Hepatology, 2016
Background and Aims. This study analyzed the risk of clinical trial failure of new drugs for hepatitis C between January 1998 and January 2015. Methods. Hepatitis C drug development trials that were in phases I–III of clinical trial testing were obtained
Nicole A. Tillie, Jayson L. Parker, Jordan J. Feld   +2 more
doaj   +1 more source

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction : role of vorapaxar [PDF]

, 2015
© 2015 Farag et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) LicenseAcute myocardial infarction (AMI) is generally attributed to coronary atherothrombotic ...
Farag, Mohamed, Gorog, Diana A, Patel, Hiten   +2 more
core   +3 more sources